vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $15.0M, roughly 1.8× CHAMPIONS ONCOLOGY, INC.). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs 1.8%, a 37.5% gap on every dollar of revenue. On growth, WEST BANCORPORATION INC posted the faster year-over-year revenue change (16.6% vs 11.5%). WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $-2.0M). Over the past eight quarters, WEST BANCORPORATION INC's revenue compounded faster (17.3% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
CSBR vs WTBA — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $26.9M |
| Net Profit | $268.0K | $10.6M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | 50.0% |
| Net Margin | 1.8% | 39.2% |
| Revenue YoY | 11.5% | 16.6% |
| Net Profit YoY | -63.2% | 34.8% |
| EPS (diluted) | $0.02 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | $15.0M | $24.2M | ||
| Q3 25 | $14.0M | $25.0M | ||
| Q2 25 | $12.4M | $23.8M | ||
| Q1 25 | $17.0M | $23.1M | ||
| Q4 24 | $13.5M | $20.9M | ||
| Q3 24 | $14.1M | $20.3M | ||
| Q2 24 | $14.0M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | $268.0K | $7.4M | ||
| Q3 25 | $-436.0K | $9.3M | ||
| Q2 25 | $-1.8M | $8.0M | ||
| Q1 25 | $4.5M | $7.8M | ||
| Q4 24 | $728.0K | $7.1M | ||
| Q3 24 | $1.3M | $6.0M | ||
| Q2 24 | $-109.0K | $5.2M |
| Q1 26 | — | — | ||
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — |
| Q1 26 | — | 50.0% | ||
| Q4 25 | 1.2% | 39.6% | ||
| Q3 25 | -3.8% | 45.8% | ||
| Q2 25 | -16.2% | 43.4% | ||
| Q1 25 | 26.4% | 43.4% | ||
| Q4 24 | 5.4% | 30.9% | ||
| Q3 24 | 9.5% | 36.6% | ||
| Q2 24 | -1.9% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | 1.8% | 30.7% | ||
| Q3 25 | -3.1% | 37.3% | ||
| Q2 25 | -14.9% | 33.5% | ||
| Q1 25 | 26.4% | 34.0% | ||
| Q4 24 | 5.4% | 34.0% | ||
| Q3 24 | 9.3% | 29.3% | ||
| Q2 24 | -0.8% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | $0.02 | $0.44 | ||
| Q3 25 | $-0.03 | $0.55 | ||
| Q2 25 | $-0.12 | $0.47 | ||
| Q1 25 | $0.31 | $0.46 | ||
| Q4 24 | $0.05 | $0.41 | ||
| Q3 24 | $0.09 | $0.35 | ||
| Q2 24 | $-0.01 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $362.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $270.7M |
| Total Assets | $30.2M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | $8.5M | $471.1M | ||
| Q3 25 | $10.3M | $232.9M | ||
| Q2 25 | $9.8M | $345.2M | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | $2.8M | $243.5M | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $2.6M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | $4.2M | $266.0M | ||
| Q3 25 | $3.5M | $255.1M | ||
| Q2 25 | $3.8M | $240.9M | ||
| Q1 25 | $5.5M | $237.9M | ||
| Q4 24 | $681.0K | $227.9M | ||
| Q3 24 | $-332.0K | $235.4M | ||
| Q2 24 | $-1.9M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $30.2M | $4.1B | ||
| Q3 25 | $30.5M | $4.0B | ||
| Q2 25 | $32.3M | $4.1B | ||
| Q1 25 | $30.6M | $4.0B | ||
| Q4 24 | $25.2M | $4.0B | ||
| Q3 24 | $24.9M | $4.0B | ||
| Q2 24 | $26.1M | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $12.9M |
| Free Cash FlowOCF − Capex | $-2.0M | $12.4M |
| FCF MarginFCF / Revenue | -13.1% | 46.0% |
| Capex IntensityCapex / Revenue | 1.6% | 1.8% |
| Cash ConversionOCF / Net Profit | -6.47× | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | $-1.7M | $46.5M | ||
| Q3 25 | $600.0K | $11.4M | ||
| Q2 25 | $6.9M | $13.5M | ||
| Q1 25 | $490.0K | $9.7M | ||
| Q4 24 | $-283.0K | $39.8M | ||
| Q3 24 | $311.0K | $12.9M | ||
| Q2 24 | $-1.8M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | $-2.0M | $43.2M | ||
| Q3 25 | $554.0K | $10.8M | ||
| Q2 25 | $6.6M | $12.8M | ||
| Q1 25 | $448.0K | $8.3M | ||
| Q4 24 | $-377.0K | $13.7M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | $-1.8M | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | -13.1% | 178.3% | ||
| Q3 25 | 4.0% | 43.0% | ||
| Q2 25 | 53.5% | 53.6% | ||
| Q1 25 | 2.6% | 35.7% | ||
| Q4 24 | -2.8% | 65.6% | ||
| Q3 24 | — | 34.2% | ||
| Q2 24 | -13.0% | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | 1.6% | 13.7% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 2.0% | 3.2% | ||
| Q1 25 | 0.2% | 6.5% | ||
| Q4 24 | 0.7% | 125.3% | ||
| Q3 24 | 0.0% | 29.4% | ||
| Q2 24 | 0.0% | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | -6.47× | 6.26× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.70× | ||
| Q1 25 | 0.11× | 1.24× | ||
| Q4 24 | -0.39× | 5.61× | ||
| Q3 24 | 0.24× | 2.17× | ||
| Q2 24 | — | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
WTBA
Segment breakdown not available.
